BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is 71.53% higher on its value in year-to-date trading and has touched a low of $2.35 and a high of $62.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BVXV stock was last observed hovering at around $5.08 in the last trading session, with the day’s loss setting it -0.26% off its average median price target of $30.00 for the next 12 months. It is also 83.93% off the consensus price target high of $30.00 offered by 1 analysts, but current levels are 83.93% higher than the price target low of $30.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $4.82, the stock is -7.07% and 15.74% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.0 million and changing -5.12% at the moment leaves the stock -76.84% off its SMA200. BVXV registered -47.32% loss for a year compared to 6-month loss of -86.39%. The firm has a 50-day simple moving average (SMA 50) of $4.6106 and a 200-day simple moving average (SMA200) of $17.6210.
The stock witnessed a -18.99% gain in the last 1 month and extending the period to 3 months gives it a 73.38%, and is -8.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.04% over the week and 13.86% over the month.
Distance from 52-week low is 105.11% and -92.23% from its 52-week high.
BiondVax Pharmaceuticals Ltd. (BVXV) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for BiondVax Pharmaceuticals Ltd. (BVXV) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
BiondVax Pharmaceuticals Ltd. is expected to release its quarterly report on 06/01/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 0.40% this year.
BiondVax Pharmaceuticals Ltd. (BVXV) Top Institutional Holders
20 institutions hold shares in BiondVax Pharmaceuticals Ltd. (BVXV), with 4.27M shares held by insiders accounting for 37.10% while institutional investors hold 6.45% of the company’s shares. The shares outstanding are 10.84M, and float is at 7.74M with Short Float at 12.57%. Institutions hold 4.06% of the Float.
The top institutional shareholder in the company is Morgan Stanley with over 48666.0 shares valued at $1.9 million. The investor’s holdings represent 0.43% of the BVXV Shares outstanding. As of Sep 29, 2020, the second largest holder is ARK Investment Management, LLC with 19856.0 shares valued at $0.78 million to account for 0.17% of the shares outstanding. The other top investors are State Street Corporation which holds 16489.0 shares representing 0.15% and valued at over $0.64 million, while Mutual Advisors, LLC holds 0.06% of the shares totaling 7151.0 with a market value of $0.28 million.